diabetes therapies articles & resources on Made-in-China.com

Sanofi Has Released Results of a 24-Week Phase Iiib Clinical Trial

Dec 9, 2013

Sanofi has released results of a 24-week Phase IIIb clinical trial showing that Lyxumia (lixisenatide) met the primary endpoint of non-inferiority in blood sugar lowering (HbA1c) when administered to patients either before breakfast or the ...

Tags: Diabetes Drug, Medicine

Japan-Based Takeda Pharma Has Received Positive CHMP Opinion

Jul 30, 2013

Japan-based Takeda Pharma has received positive CHMP opinion for its three new type 2 diabetes therapies from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The therapies include Vipidia ...

Tags: Therapies, CHMP Opinion

Takeda Has Received FDA Approval for Three New Type 2 Diabetes Therapies Nesina

Jan 30, 2013

Takeda Pharmaceutical has received FDA approval for three new type 2 diabetes therapies Nesina (alogliptin) and fixed-dose combinations Oseni (alogliptin and pioglitazone) and Kazano (alogliptin and metformin HCl). Takeda expects to ...

Tags: FDA, diabetes therapies, Pharmaceuticals

Novo Nordisk Anticipates Launching Tresiba, Brand Name of Insulin Degludec

Jan 23, 2013

The European Commission has issued clearance to market Novo Nordisk's diabetes therapies, Tresiba and Ryzodeg, across 27 European Union (EU) states. Novo Nordisk anticipates launching Tresiba, brand name of insulin degludec, in the UK and ...

Tags: Ryzodeg diabetes drugs, injection doses, diabetes therapies

diabetes therapies

Sanofi Has Released Results of a 24-Week Phase Iiib Clinical Trial

Japan-Based Takeda Pharma Has Received Positive CHMP Opinion

Takeda Has Received FDA Approval for Three New Type 2 Diabetes Therapies Nesina

Novo Nordisk Anticipates Launching Tresiba, Brand Name of Insulin Degludec

Related Products